Read More

In a large pharmaceutical client’s double-blind study in severe infectious disease, the patients failed to meet the primary endpoint. A subset of the patients showed benefit with the treatment, but a variety of simple sub-group analyses were unable to identify which patients could benefit from active treatment versus standard of care.

Cytel used machine learning (ML) to help the client identify a subset of patients that could potentially benefit from their treatment.